key: cord-1006357-amsb2xfr
authors: Vogel, Annette B.; Kanevsky, Isis; Che, Ye; Swanson, Kena A.; Muik, Alexander; Vormehr, Mathias; Kranz, Lena M.; Walzer, Kerstin C.; Hein, Stephanie; Güler, Alptekin; Loschko, Jakob; Maddur, Mohan S.; Ota-Setlik, Ayuko; Tompkins, Kristin; Cole, Journey; Lui, Bonny G.; Ziegenhals, Thomas; Plaschke, Arianne; Eisel, David; Dany, Sarah C.; Fesser, Stephanie; Erbar, Stephanie; Bates, Ferdia; Schneider, Diana; Jesionek, Bernadette; Sänger, Bianca; Wallisch, Ann-Kathrin; Feuchter, Yvonne; Junginger, Hanna; Krumm, Stefanie A.; Heinen, André P.; Adams-Quack, Petra; Schlereth, Julia; Schille, Stefan; Kröner, Christoph; de la Caridad Güimil Garcia, Ramón; Hiller, Thomas; Fischer, Leyla; Sellers, Rani S.; Choudhary, Shambhunath; Gonzalez, Olga; Vascotto, Fulvia; Gutman, Matthew R.; Fontenot, Jane A.; Hall-Ursone, Shannan; Brasky, Kathleen; Griffor, Matthew C.; Han, Seungil; Su, Andreas A.H.; Lees, Joshua A.; Nedoma, Nicole L.; Mashalidis, Ellene H.; Sahasrabudhe, Parag V.; Tan, Charles Y.; Pavliakova, Danka; Singh, Guy; Fontes-Garfias, Camila; Pride, Michael; Scully, Ingrid L.; Ciolino, Tara; Obregon, Jennifer; Gazi, Michal; Carrion, Ricardo; Alfson, Kendra J.; Kalina, Warren V.; Kaushal, Deepak; Shi, Pei-Yong; Klamp, Thorsten; Rosenbaum, Corinna; Kuhn, Andreas N.; Türeci, Özlem; Dormitzer, Philip R.; Jansen, Kathrin U.; Sahin, Ugur
title: BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
date: 2020-12-11
journal: bioRxiv
DOI: 10.1101/2020.12.11.421008
sha: 3d00ff4c8f676918f1b0375f3f6a35bf0bb7219b
doc_id: 1006357
cord_uid: amsb2xfr

A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleoside-modified mRNA encoding SARS-CoV-2 spike glycoprotein-derived immunogens. BNT162b1 encodes a soluble, secreted, trimerised receptor-binding domain (RBD-foldon). BNT162b2 encodes the full-length transmembrane spike glycoprotein, locked in its prefusion conformation (P2 S). The flexibly tethered RBDs of the RBD-foldon bind ACE2 with high avidity. Approximately 20% of the P 2S trimers are in the two-RBD ‘down,’ one-RBD ‘up’ state. In mice, one intramuscular dose of either candidate elicits a dose-dependent antibody response with high virus-entry inhibition titres and strong TH1 CD4+ and IFNγ+ CD8+ T-cell responses. Prime/boost vaccination of rhesus macaques with BNT162b candidates elicits SARS-CoV-2 neutralising geometric mean titres 8.2 to 18.2 times that of a SARS-CoV-2 convalescent human serum panel. The vaccine candidates protect macaques from SARS-CoV-2 challenge, with BNT162b2 protecting the lower respiratory tract from the presence of viral RNA and with no evidence of disease enhancement. Both candidates are being evaluated in phase 1 trials in Germany and the United States. BNT162b2 is being evaluated in an ongoing global, pivotal Phase 2/3 trial (NCT04380701, NCT04368728).

Characterisation of antigen-specific splenic T-cell responses in mice 12 and 28 days after 171

BNT162b vaccine immunisation revealed a high fraction of CD4 + and CD8 + T cells that 172 produced IFNγ and CD8 + cells that produced IL-2, as shown by enzyme linked immunospot 173 assay (ELISpot) or intracellular cytokine staining (ICS) flow cytometry analysis after ex vivo 174 restimulation with a full-length S peptide pool (Fig. 3a-c) . Total splenocytes harvested on Day 175 28 and re-stimulated with the full-length S peptide pool secreted high levels of the TH1 176 cytokines IL-2 or IFNγ and minute or undetectable levels of the TH2 cytokines IL-4, IL-5 or IL-177 13, as measured in multiplex immunoassays (Fig. 3d) . Overall, the patterns of CD4 + and CD8 + 178 T-cell responses were similar for the two vaccine candidates, with a somewhat stronger IFNγ-179 producing CD8 + T-cell response in BNT162b2-immunised mice. 12 days after immunisation with 5 g of either vaccine as compared to control (Extended Data 187 Fig. 4a, b) . Vaccine-immunised mice had significantly fewer circulating B cells than control 188 sampling (2 of 6 on Day 6), and from none of the BNT162b2-immunised macaques on any 252 sampling. Similar patterns were seen in OP and rectal swabs, with viral RNA more often 253 detected in control-immunised macaques than in BNT162b1-or BNT162b2-immunised 254 macaques and with more persistence of viral RNA in rectal swabs than in OP swabs (Extended 255 Data Fig. 7a, b) . 256

At the time of challenge, SARS-CoV-2 neutralising titres ranged from 208 to 1,185 in the 257 BNT162b1-immunised animals and from 260 to 1,004 in the BNT162b2-immunised animals. 258 Neutralising titres were below the limit of detection in the control animals (Fig. 5c, d) . were not consistently associated with viral challenge (Extended Data Fig. 9a, b) . 270

Histopathology of necropsy specimens obtained 7-8 days after challenge revealed localised 271 areas of pulmonary inflammation that were limited in extent even in the control animals 272 challenged after mock immunisation with saline (Extended Data Fig. 10 ). We conclude that the 273 2-4 year old male rhesus macaque challenge model is primarily a SARS-CoV-2 infection model 274 rather than a COVID-19 disease model. 275

We demonstrate that BNT162b1 or BNT162b2, LNP-formulated, m1Ψ nucleoside-modified 277 mRNAs that encode secreted, trimerised SARS-CoV-2 RBD or prefusion-stabilised S, 278 respectively, induce strong antigen-specific immune responses in mice and rhesus macaques. 279

The RBD-foldon coding sequence directs the expression and secretion of a flexible, trimeric 280 protein that binds ACE2 with high affinity and has structurally intact ACE2 receptor binding 281 sites. Protein expressed from DNA with the BNT162b2-encoded P2 S amino acid sequence was 282 confirmed to be in the prefusion conformation by cryo-EM. This analysis showed that the 283 antigenically important RBD can assume the 'up' conformation, with the receptor binding site, 284 rich in neutralising epitopes, accessible in a proportion of the molecules 24 . The alternative states 285 observed likely reflect a dynamic equilibrium between RBD 'up' and 'down' positions 7,26 . 286

Binding of expressed and purified P2 S to ACE2 and a neutralising monoclonal antibody further 287 demonstrates its conformational and antigenic integrity. 288

In mice, a single sub-microgram immunisation with either BNT162b candidate rapidly induced 289 high antibody titres that inhibited pseudovirus entry in the range of or above recently reported 290 neutralising titres elicited by other SARS-CoV-2 vaccine candidates 29,30 . The candidates also 291 induced strong TFH and TH1 type CD4 + T-cell responses, the latter thought to be a more general 292 effect of LNP-formulated modRNA vaccines against SARS-CoV-2 31 . Both CD4 + T-cell types 293 are known to support antigen-specific antibody generation and maturation. In some animal 294 models of respiratory virus infection, a TH2 type CD4 + T-cell response has been associated with 295 vaccine-associated enhanced respiratory disease 32,33 . Therefore, a TH1 type response to 296 immunisation is preferred, as it may reduce the theoretical risk of enhanced pulmonary disease 297 during subsequent viral infection. Immunisation with the vaccine candidates triggered 298 redistribution of B cells from the blood to lymphoid tissues, where antigen presentation occurs. 299

In humans, TFH cells in the circulation after vaccination with a VSV-vectored Ebola vaccine 300 candidate have been correlated with a high frequency of antigen-specific antibodies 34 . After 301 vaccination of mice with BNT162b1 or BNT162b2, high numbers of TFH were present in both 302 blood and LN, a potential correlate for the generation of a strong adaptive B-cell response in 303 germinal centres. In addition to eliciting favourable CD4 + T-cell responses, both BNT162b1 304 and BNT162b2 elicit CD8 + T-cell responses in mice, with BNT162b2 appearing to be 305 somewhat more efficient at eliciting antigen-specific cytotoxic IFNγ CD8 + T cells. 306 BNT162b1 and BNT162b2 elicit immune profiles in rhesus macaques similar to those observed 307 in mice. Seven days after Dose 2 of 100 µg administered to macaques, during the expansion 308 phase of the antibody response, neutralising GMTs elicited by either candidate reached 309 approximately 18-times the GMT of a human SARS-CoV-2 convalescent serum panel. Neutralising GMTs declined by Day 56 (35 days after Dose 2), consistent with the contraction 311 phase, but remained well above the GMT of the panel. The duration of the study was not long 312 enough to assess the rate of decline during the plateau phase of the antibody response. As it 313

Limitation and clearance of virus infections is promoted by the interplay of neutralising 316 antibodies that eliminate infectious particles with CD8 + T cells that target intracellular virus 317 reservoirs. CD8 + T cells may also reduce the influx of monocytes into infected lung tissue, 318 which can be associated with undesirable IL-6 and TNF production and impaired antigen 319 Purified recombinant SARS-CoV-2 RBD (Sino Biological) or trimeric S protein (Acro 515 Biosystems) was used as a target for western blot, and the RBD tagged with a human Fc (Sino 516 Biological) was used in ELISA to detect SARS-CoV-2 S-specific IgG. A recombinant SARS-517

CoV-2 RBD containing a C-terminal Avitag™ (Acro Biosystems) was used as a target antigen 518 in Luminex immunoassays. Purified recombinant SARS-CoV-2 S1 including a histidine tag 519 (Sino Biological) was used in ELISA to detect SARS-CoV-2 S-specific IgG in mice. Purified 520 recombinant SARS-CoV-2 S1 and RBD with histidine tags (both Sino Biological) were used 521 for surface plasmon resonance (SPR) spectroscopy. A peptide pool of 15-mer peptides 522 irrelevant peptide (SPSYVYHQF, derived from gp70 AH-1 38 ) or a CMV peptide pool was used 525 as control for ELISpot assays. All peptides were obtained from JPT Peptide Technologies. 526

Human convalescent sera. Fig. 1 ). The gel filtration column was calibrated with well defined 578 protein standards separated under identical conditions in a second run. Size fractioned FBS-free 579 medium from BNT162b1 RNA-transfected HEK293T cells was analysed by denaturing (95° 580 C) and non-denaturating (no-heating) PAGE using 4-15% Criterion™ TGX Stain-Free™ Gel 581 (Bio-Rad) and western blot. Transfer to a nitrocellulose membrane (Bio-Rad) was performed 582 proteins were detected with a monoclonal antibody that recognizes SARS-CoV-2 S1 584 (SinoBiological) and a secondary anti-rabbit horse radish peroxidase (HRP)-conjugated 585 antibody (Sigma Aldrich). Blots were developed with Clarity Western ECL Substrate (Bio-586 Rad) and imaged with a Fusion FX Imager (Vilber) using the Image Lab software version 6.0. Purification of the recombinant protein was based on a procedure described previously, with 634 minor modifications 6 . Upon cell lysis, P2 S was solubilised in 1% NP-40 detergent. The 635

TwinStrep-tagged protein was then captured with StrepTactin Sepharose HP resin in 0.5% NP-636 40. P2 S was further purified by size-exclusion chromatography and eluted as three distinct 637 peaks in 0.02 % NP-40 as previously reported 6 . (Chromatogram not shown.) A peak that 638 consists of intact P2 S migrating at around 150 kDa, as well as dissociated S1 and S2 subunits 639 (which co-migrate at just above 75 kDa), was used in the structural characterisation. 640

Spontaneous dissociation of the S1 and S2 subunits occurs throughout the course of protein 641 purification, starting at the point of detergent-mediated protein extraction, so that P2 S 642 preparations also contain dissociated S1 and S2. of interaction (kd) with ACE2-PD was slower than the limit of measurement of the instrument, 664 and the minimum binding avidity (KD) was estimated using an assumed dissociation rate kd of 665 1 × 10 -6 s -1 . 666

Purified RBD-foldon in 4 μL was applied to a glow-discharged copper grid overlaid with 668 formvar and amorphous carbon (Ted Pella). Negative staining was performed with Nano-W 669 organotungstate stain (Nanoprobes) according to the manufacturer's protocol. Table. 1. 726

Mice. Female BALB/c mice (Janvier; 8-12 weeks) were randomly allocated to groups. 728 BNT162b1 and BNT162b2 were diluted in PBS with 300 mM sucrose ( Fig. 2 and Fig. 3b, d for  729 BNT162b2, and Extended Data Fig. 3 ) or 0.9% NaCl placebo control (Fig. 3a, c and Fig. 3b, d  730 for BNT162b1, and Extended Data Fig. 4) Rhesus macaques (Macaca mulatta). Serum was obtained before, 6 hours after, and 1, 14, 21, 747 28, 35 and 42 days after immunisation with BNT162b1, BNT162b2, or saline (Extended Data 748 Table 2 ). For BNT162b2 and challenge cohort 3 controls, serum was also obtained on Day 56, 749

and PBMCs were obtained before immunisation and on Days 7, 28, and 42, except that PBMCs 750

were not obtained from the challenge cohort 3 control animals on Day 28. Blood for serum and 751

PBMCs was collected in compliance with animal protocol 2017-8725-023 approved by the 752 NIRC Institutional Animal Care and Use Committee. Animals were anesthetised with ketamine 753

HCl (10 mg/kg; IM) during blood collection and were monitored for adequate sedation. 754

Mice. MaxiSorp plates (Thermo Fisher Scientific) were coated with recombinant S1 or RBD 756

(1 µg/mL) in sodium carbonate buffer, and serum-derived, bound IgG was detected using a 757 horseradish peroxidase (HRP)-conjugated secondary antibody and tetramethylbenzidine 758 (TMB) substrate (Biotrend). Data collection was performed using a BioTek Epoch reader and 759 Gen5 software version 3.0.9. For concentration analysis, an IgG mouse isotype control was 760 used in parallel in a serial dilution, and the sample signals were correlated to a standard curve 761 of the isotype control. 762

Rhesus macaques (Macaca mulatta), humans. Recombinant SARS-CoV-2 S1 containing a C-763 terminal Avitag™ (Acro Biosystems) was bound to streptavidin-coated Luminex microspheres. 764

Bound rhesus macaque or human anti-S1 antibodies present in the serum were detected with a 765 fluorescently labelled goat anti-human polyclonal secondary antibody (Jackson 766 ImmunoResearch). Data were captured as median fluorescent intensities (MFIs) using a 767

Bioplex200 system (Bio-Rad) and converted to U/mL antibody concentrations using a reference 768 standard consisting of 5 pooled human COVID-19 convalescent serum samples (obtained 769 >14 days PCR diagnosis, from the panel described above), diluted in antibody depleted human 770 serum with arbitrary assigned concentrations of 100 U/mL and accounting for the serum 771 dilution factor. 772

Surface plasmon resonance spectroscopy of polyclonal mouse immune sera. 773

Binding kinetics of murine S1-and RBD-specific serum IgG to recombinant S1 and RBD was 774 determined using a Biacore T200 device (Cytiva) with 10 mM Hepes, 150 mM NaCl, 3 mM 775 

The SARS-CoV-2 inoculum was obtained from a stock of 2. BNT162b1-immunised (n=6), BNT162b2-immunised (n=6), and age-matched saline-921 immunised (n=9) male rhesus macaques (control) were challenged with 1.05 × 10 6 plaque 922 times relative to immunisation indicated in Extended Data Fig. 6 and Extended Data Table 2 . 927

Twelve to nineteen days prior to challenge, animals were moved from the NIRC, in New Iberia, 928 LA, where they had been immunised, to the animal biosafety level 3 facility at SNPRC (in San 929 Antonio, TX). Animals were monitored regularly by a board-certified veterinary clinician for 930 rectal body temperature, weight and physical examination. Specimen collection was performed 931 under tiletamine zolazepam (Telazol) anaesthesia as described 28 To detect and quantify SARS-CoV-2 in NHP, viral RNA was extracted from BAL fluid and 940 from nasal, OP, and rectal swabs as previously described 52-54 and tested by RT-qPCR as 941 previously described 28 . Briefly, 10 µg yeast tRNA and 1 × 10 3 PFU of MS2 phage (Escherichia 942 coli bacteriophage MS2, ATCC) were added to each thawed sample, and RNA extraction 943 performed using the NucleoMag Pathogen kit (Macherey-Nagel). The SARS-CoV-2 RT-qPCR 944 was performed on extracted RNA using a CDC-developed 2019-nCoV N1 assay on a 945

QuantStudio 3 instrument (Applied Biosystems). The cut-off for positivity (limit of detection, 946 LOD) was established at 10 gene equivalents (GE) per reaction (800 GE/mL). Samples were 947 tested in duplicate. One BAL specimen from the challenge cohort 2 control group obtained on 948 Day 6 after challenge and one nasal swab from the BNT162b1-immunised group obtained on 949 Day 1 after challenge had, on repeated measurements, viral RNA levels on either side of the 950 LLOD. These specimens were categorised as indeterminate and excluded from the graphs and 951 the analysis. 952 right and left lateral) were obtained at the times relative to challenge indicated in Extended Data 956 Table 2 . The animals were anesthetized using Telazol (2-6 mg/kg) and maintained by inhaled 957 isoflurane delivered through a Hallowell 2002 ventilator anesthesia system (Hallowell, 958

Pittsfield, MA). Animals were intubated to perform end inspiratory breath-hold using a remote 959 breath-hold switch. Lung field CT images were acquired using Multiscan LFER150 PET/CT 960 (MEDISO Inc., Budapest, Hungary) scanner. Image analysis was performed using 3D ROI tools 961 available in Vivoquant (Invicro, Boston, MA). Images were interpreted by a board-certified 962 veterinary radiologist blinded to treatment groups. Scores were assigned to a total of 7 lung 963 regions on a severity scale of 0-3 per region, with a maximum severity score of 21. Pulmonary 964 lesions evident prior to challenge, or those which could not be unequivocally attributed to the 965 viral challenge (such as atelectasis secondary to recumbency and anesthesia) received a score 966 of "0". 967

Lung histopathology is reported on necropsies performed on 2-4 year old male rhesus macaques 969 at the times after challenge indicated in Extended Data Figure 6 and Extended Data Table 2.  970 Necropsy, tissue processing, and histology were performed by SNPRC in San Antonio, TX. 971

Samples were fixed in 10% neutral buffered formalin and processed routinely into paraffin 972 blocks. Tissue blocks were sectioned to 5 µm and stained with hematoxylin and eosin. 973

Microscopic evaluation of 7 lung tissue sections per animal (1 sample of each lobe on L & R) 974 was performed blindly by SNPRC and Pfizer pathologists. Lungs were evaluated using a semi-975 quantitative scoring system with inclusion of cell types and/or distribution as appropriate. 976

Inflammation score was based on area of tissue in section involved: 0 = normal; 1=<10%; 2=11-977 30%; 3=30-60%; 4= 60-80%; 5=>80%. Each lobe received an individual score, and the final 978 score for each animal was reported as the mean of the individual scores. The pathologists were 979 unblinded to the group assignments after agreement on diagnoses. As indicated in Extended 980 Data Fig. 6 and Extended Data Table 2 The data that support the findings of this study are available from the corresponding author 996 upon reasonable request. 997 

A pneumonia outbreak associated with a new coronavirus of probable bat U.S. conceived and conceptualised the work and strategy

designed primers, performed oligosynthesis, cloned constructs and 1018 performed protein expression experiments

developed ACE2/B 0 AT1/RBD-trimer formation and 1021 purified the complex. P.V.S. developed and performed biolayer interferometry experiments

performed electron microscopy and solved the structure of the complex. Y.C. 1023 supervised the structural and biophysical characterisation and analysed the structures

performed surface plasmon resonance spectroscopy

designed mouse studies, analysed and interpreted data

1028 designed and optimized MS2-SARS-nCoV-2-N1 RT-qPCR assay

1035 read and interpreted radiographs and CT scan. O.G. and S.C. read and interpreted 1036 histopathology specimens

1039 provided veterinary services for NHPs

V. contributed to synthesis and integrated interpretation of 1041 obtained data

wrote the manuscript. All authors supported the review of the manuscript

BNT162b2, determined by bead-based multiplex analysis (BNT162b2: n=7 for IL-4, IL-5 and 1124 IL-13

Human convalescent sera 1131 (HCS) were obtained from SARS-CoV-2-infected patients at least 14 days after PCR-confirmed 1132 diagnosis and at a time when acute COVID-19 symptoms had resolved (n=38). The HCS panel 1133 is a benchmark for serology studies in this and other manuscripts. a, Concentrations, in arbitrary 1134 units

Heights of bars indicate the geometric (a-b) or 1140 arithmetic (c-g) means for each group, with values written above bars (a-b). Whiskers indicate 1141 95% confidence intervals (CI's; a-b) or standard errors of means (SEMs; c-g). Each symbol 1142 represents one animal. Horizontal dashed lines mark LLODs. For serology and ELISpot data 1143 (a-d) but not for flow cytometry data

Arrows below the x-axis indicate the days of Doses 1 and 2. 1145 1146 medium. Macaque assignments to cohorts and schedules of immunisation, challenge, and 1155 sample collection are provided in Extended Data Fig. 6 and Extended Data Table 2. Viral RNA 1156 levels were detected by RT-qPCR. a, Viral RNA

Viral RNA in nasal swabs. Symbols represent individual animals. Ratios above bars indicate 1158 the number of viral RNA positive animals among all animals in a group with evaluable samples

Values below the LLOD were set to ½ the LLOD. The statistical 1162 significance by a non-parametric test (Friedman's test) of differences in viral RNA detection 1163 after challenge between 6 BNT162b1-immunised and 6 mock-immunised animals (challenge 1164 cohorts 1 and 2) was p = 0.015 for BAL fluid and p = 0.005 for nasal swab

Serum 1167 samples were assayed for SARS-CoV-2 50% neutralisation titres (VNT50). c, BNT162b1-1168 immunised macaques and Controls (challenge cohorts 1 and 2). d, BNT162b2-immunised 1169 macaques and Controls

Extended Data Figure 1. Vaccine antigen expression and receptor affinity. 1173 (BNT162b1, BNT162b2) or BNT162b RNAs mixed with a transfection reagent

BNT162b2 RNA). b, Localisation of BNT162b1 RNA-encoded RBD-foldon or

BNT162b2 RNA-encoded P2 S in HEK293T cells transfected as in panel a, determined by 1179 immunofluorescence staining

Scale bar: 10 µm. c, Western blot of denatured and non-denatured samples of 1181 size exclusion chromatography (SEC) fractions (chromatogram in Supplementary Fig. 1) of 1182 concentrated medium from HEK293T cells transfected with BNT162b1 RNA. The RBD-foldon 1183 was detected with a rabbit monoclonal antibody against the S1

Biolayer interferometry 1185 sensorgram demonstrating the binding kinetics of the purified RBD-foldon trimer, expressed 1186 from DNA, to immobilised human ACE2-PD. e,f Biolayer inferometry sensorgrams showing 1187 binding of a DNA-expressed P2 S preparation from a size exclusion chromatography peak (not 1188 shown) that contains intact P2 S and dissociated S1 and S2 to immobilised (e) human ACE2-1189 PD and (f) B38 monoclonal antibody. Binding data are in colour; 1:1 binding models fit to the 1190 data are in black

2D class averages of TwinStrep-tagged P2 S particles

Box edge: 39.2 nm. b, Fourier shell correlation curve from RELION gold-1195 standard refinement of the P2 S trimer. c, Flowchart for cryo-EM data processing of the 1196 complex

Extended Data Figure 3. BNT162b-elicited antibody responses in mice

ANOVA [c], all using Dunnett's multiple comparisons test) are provided. a, b, RBD-1203 and S1-specific IgG responses in sera obtained 7, 14, 21 and 28 days after immunisation with

For day 0 values, a pre-screening of 1205 randomly selected mice was performed (n=4). c, Reciprocal serum endpoint titres of RBD-1206 specific IgG 14 days after immunisation. The horizontal dotted line indicates the lower limit of 1207 detection (LLOD). d, Representative surface plasmon resonance sensorgram of the binding 1208 kinetics of His-tagged S1 to immobilised mouse IgG from serum drawn 28 days after 1209 immunisation with 5 µg BNT162b2

Lines represent 1213 individual sera. Horizontal dotted lines indicate geometric mean ± 95% CI (as grey area) of 1214 infected cells in the absence of mouse serum (virus positive control). g, Pearson correlation of 1215 pseudovirus-based VSV-SARS-CoV-2 50% neutralisation titres with live SARS-CoV-2 virus 1216 neutralisation titres for n = 10 random selected serum samples from mice immunised with 1217 BNT162b1 and BNT162b2 each

Cell subset composition was determined by flow cytometry. P-values were 1223 determined by a two-tailed unpaired t-test. a, B-cell and T-cell numbers in draining lymph 1224 nodes (popliteal, iliac and inguinal lymph nodes; dLN) (for B-cell subtyping: control

Extended Data Figure 7. Viral RNA detection in oropharyngeal (OP) and rectal swabs 1245 from rhesus macaques after BNT162b immunisation and challenge with infectious SARS-1246

Rhesus macaques immunised with 100 µg of BNT162b1 or BNT162b2 (n=6 each) and 1248 macaques immunised with saline or not immunised (Control, n=9), as described in Fig

Additional macaques (sentinel, n=6) were mock-challenged with cell culture 1252 medium. Viral RNA levels were detected by RT-qPCR. a, Viral RNA in OP swabs. b, Viral 1253 RNA in rectal swabs. Ratios above data points indicate the number of viral RNA positive 1254 animals among all animals providing evaluable samples in a group. Heights of bars indicate 1255 geometric mean of viral RNA copies; whiskers indicate geometric standard deviations. Every challenge was p < 0.001 for OP swabs and p = 0.118 for rectal swabs; between 6 BNT162b2-1261 immunised animals and 3 contemporaneously control-immunised animals (challenge cohort 3) 1262 after challenge, the statistical significance was p < 0.001 for OP swabs and p = 0.221 for rectal 1263 swabs

Rhesus macaques were immunised with BNT162b vaccine candidates (n=6 per group) or saline 1268 (control; n=9) and challenged with SARS-CoV-2. A sentinel group was challenged with cell 1269 culture medium (n=6) as described in Figs. 4 and 5 and Extended Data Table 2. Vital signs were 1270 recorded. a, Body weight change. b, Temperature change

Radiographic signs in rhesus macaques after immunisation with 1273 BNT162b1 or BNT162b2 and challenge with SARS-CoV-2

or saline (control) and 1275 challenged with SARS-CoV-2. A sentinel group was challenged with cell culture medium and 1276 imaged as described in Figs. 4 and 5 and Extended Data Table 2. Three-view thoracic 1277 radiographs (ventrodorsal, right and left lateral) and lung field CT images were obtained prior 1278 to challenge (pre), and post-challenge at the indicated time points. The animals were 1279 anesthetised and intubated to perform end inspiratory breath-hold

Supplementary Figure 3. Gating strategy for flow cytometry analysis of mouse data 1318 shown in Figure 3 c

Flow cytometry gating strategy for the identification of IFNγ, IL-2, and TNF secreting CD8 + T 1320 cells in the mouse spleen. a, CD8 + T cells were gated within single

IL-2 and TNF in CD8 + T cells

Supplementary Figure 5. Gating strategy for flow cytometry analysis of data shown in 1335

Extended Data Figure 1a

Flow cytometry gating strategy for the identification of HEK293T cells transfected with

BNT162b1 or BNT162b2, or BNT162b1-RNA or BNT162b2-RNA using a transfection reagent 1338 or no RNA (control). S1 + HEK293T cells were gated within single

Mottl, J. Mühl and P. Windecker supported the mouse studies and serological analysis with 1008 excellent technical assistance. We thank radiologists A. K. Voges and E. Clemmons for 1009 interpreting radiographs for the nonhuman primate study and S. Ganatra for radiology services. 1010We thank E. Romero for veterinary services and K.A. Soileau and the staff of the New Iberia 1011Research Centre for non-human primate care. We thank E.J. Dick for veterinary pathology. We 1012 thank Polymun Scientific for excellent formulation services as well as Acuitas Therapeutics for BioNTech is the Sponsor of the study, and Pfizer is its agent. BioNTech and Pfizer are 1065 responsible for the design, data collection, data analysis, data interpretation, and writing of the 1066 report. The corresponding authors had full access to all the data in the study and had final 1067 responsibility for the decision to submit the data for publication. This study was not supported 1068 by any external funding at the time of submission. 1069

Supplementary Information is available for this study. 1071Correspondence and requests for materials should be addressed to Ugur Sahin. and CD8 + T cells were gated from CD3 + CD19cells. b, TFH cells were gated from CD4 + T cells 1363 and defined as CD4 + T-bet -GATA3 -CD44 + CD62L -PD-1 + CXCR5 + cells. 1364